Published in Intern Emerg Med on May 09, 2013
Major factors for facilitating change in behavioral strategies to reduce obesity. Psychol Res Behav Manag (2013) 0.90
A standard ballroom and Latin dance program to improve fitness and adherence to physical activity in individuals with type 2 diabetes and in obesity. Diabetol Metab Syndr (2014) 0.86
Role of diet on non-alcoholic fatty liver disease: An updated narrative review. World J Hepatol (2015) 0.83
Association between blood lipid levels and personality traits in young Korean women. PLoS One (2014) 0.78
Physical activity support or weight loss counseling for nonalcoholic fatty liver disease? World J Gastroenterol (2014) 0.78
Relation between usual daily walking time and metabolic syndrome. Niger Med J (2014) 0.76
Effect of laser acupuncture combined with a diet-exercise intervention on metabolic syndrome in post-menopausal women. J Adv Res (2014) 0.75
Prevalence of dyslipidemia and associated factors among the hypertensive population from rural Northeast China. BMC Public Health (2015) 0.75
Age-related reduction and independent predictors of toe flexor strength in middle-aged men. J Foot Ankle Res (2017) 0.75
The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology (2007) 6.68
Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology (2002) 6.62
Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology (2010) 5.24
Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology (2005) 5.11
Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology (2005) 4.86
Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology (2008) 4.28
A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol (2010) 3.53
Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology (2005) 3.44
Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients. J Hepatol (2013) 3.20
A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol (2005) 3.17
Carotid atherosclerosis and chronic hepatitis C: a prospective study of risk associations. Hepatology (2012) 3.04
Retinol-binding protein 4: a new marker of virus-induced steatosis in patients infected with hepatitis c virus genotype 1. Hepatology (2008) 2.91
Insulin resistance is a risk factor for esophageal varices in hepatitis C virus cirrhosis. Hepatology (2009) 2.87
Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology (2004) 2.41
Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care (2011) 2.16
HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology (2009) 2.07
Weight loss expectations in obese patients and treatment attrition: an observational multicenter study. Obes Res (2005) 2.04
Sexuality and psychopathological aspects in premenopausal women with metabolic syndrome. J Sex Med (2014) 1.99
Obesity-associated liver disease. J Clin Endocrinol Metab (2008) 1.86
Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity. J Hepatol (2010) 1.78
Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab (2005) 1.73
Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol (2005) 1.71
Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. Hepatology (2009) 1.71
Behavior therapy for nonalcoholic fatty liver disease: The need for a multidisciplinary approach. Hepatology (2008) 1.68
ESPEN Guidelines on Parenteral Nutrition: hepatology. Clin Nutr (2009) 1.63
Insulin resistance and necroinflammation drives ductular reaction and epithelial-mesenchymal transition in chronic hepatitis C. Gut (2010) 1.59
Intrauterine growth retardation, insulin resistance, and nonalcoholic fatty liver disease in children. Diabetes Care (2007) 1.58
Managing the combination of nonalcoholic fatty liver disease and metabolic syndrome. Expert Opin Pharmacother (2011) 1.55
Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol (2007) 1.41
Metabolic syndrome and health-related quality of life: does psychological well-being matter? Ann Epidemiol (2008) 1.40
Compulsive exercise to control shape or weight in eating disorders: prevalence, associated features, and treatment outcome. Compr Psychiatry (2008) 1.37
Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. Am J Gastroenterol (2008) 1.28
Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment. Best Pract Res Clin Gastroenterol (2004) 1.16
Diabetes and liver disease: an ominous association. Nutr Metab Cardiovasc Dis (2007) 1.16
Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression. Liver Transpl (2008) 1.11
Cognitive-behavioral strategies to increase the adherence to exercise in the management of obesity. J Obes (2010) 1.11
Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study. Clin Ther (2008) 1.11
Metabolic syndrome and NASH. Clin Liver Dis (2007) 1.08
NASH: from liver diseases to metabolic disorders and back to clinical hepatology. Hepatology (2002) 1.04
Lifestyle modification in the management of the metabolic syndrome: achievements and challenges. Diabetes Metab Syndr Obes (2010) 1.03
Psychological variables associated with weight loss in obese patients seeking treatment at medical centers. J Am Diet Assoc (2009) 1.02
Construct validity of the Short Form-36 Health Survey and its relationship with BMI in obese outpatients. Obesity (Silver Spring) (2006) 1.02
Weight loss expectations in obese patients seeking treatment at medical centers. Obes Res (2004) 1.02
Hyperinsulinemia and insulin resistance are independently associated with plasma lipids, uric acid and blood pressure in non-diabetic subjects. The GISIR database. Nutr Metab Cardiovasc Dis (2007) 0.98
Clinical and psychological correlates of health-related quality of life in obese patients. Health Qual Life Outcomes (2010) 0.97
Glucagon-like peptide 1-based drugs and pancreatic safety. JAMA Intern Med (2013) 0.96
Night eating syndrome and weight loss outcome in obese patients. Int J Eat Disord (2011) 0.95
NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes. Curr Diab Rep (2007) 0.95
The effect of lifestyle changes in non-alcoholic fatty liver disease. Dig Dis (2010) 0.95
Double heterozygous mutations involving both HNF1A/MODY3 and HNF4A/MODY1 genes: a case report. Diabetes Care (2010) 0.93
Psychological distress in morbid obesity in relation to weight history. Obes Surg (2007) 0.93
Stage of change and motivation to healthier lifestyle in non-alcoholic fatty liver disease. J Hepatol (2012) 0.92
Pilot study on the additive effects of berberine and oral type 2 diabetes agents for patients with suboptimal glycemic control. Diabetes Metab Syndr Obes (2012) 0.91
Major factors for facilitating change in behavioral strategies to reduce obesity. Psychol Res Behav Manag (2013) 0.90
Preliminary study about the possible glycemic clinical advantage in using a fixed combination of Berberis aristata and Silybum marianum standardized extracts versus only Berberis aristata in patients with type 2 diabetes. Clin Pharmacol (2013) 0.90
Weight management, psychological distress and binge eating in obesity. A reappraisal of the problem. Appetite (2009) 0.90
Is amenorrhea a clinically useful criterion for the diagnosis of anorexia nervosa? Behav Res Ther (2008) 0.90
Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection. Antivir Ther (2009) 0.89
Gender, fatty liver and GGT. Hepatology (2006) 0.89
Predicting intracranial lesions by antiplatelet agents in subjects with mild head injury. J Neurol Neurosurg Psychiatry (2010) 0.89
Gallstone disease is associated with more severe liver damage in patients with non-alcoholic fatty liver disease. PLoS One (2012) 0.89
PNPLA3 GG genotype and carotid atherosclerosis in patients with non-alcoholic fatty liver disease. PLoS One (2013) 0.88
Quality of diabetes care in Italy: information from a large population-based multiregional observatory (ARNO diabetes). Diabetes Care (2012) 0.88
Metabolic syndrome and insulin resistance in subjects with morbid obesity. Obes Surg (2009) 0.88
The role of lifestyle change in the prevention and treatment of NAFLD. Curr Pharm Des (2013) 0.87
Prevention and treatment of nonalcoholic fatty liver disease. Dig Liver Dis (2010) 0.87
Antiplatelet therapy and the outcome of subjects with intracranial injury: the Italian SIMEU study. Crit Care (2013) 0.87
Clinical performance of NICE recommendations versus NCWFNS proposal in patients with mild head injury. J Neurotrauma (2005) 0.87
Treatment of non-alcoholic fatty liver disease with focus on emerging drugs. Expert Opin Emerg Drugs (2011) 0.87
Personality features of obese women in relation to binge eating and night eating. Psychiatry Res (2012) 0.87
High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis. Dig Liver Dis (2011) 0.86
Health and ageing: a cross-sectional study of body composition. Clin Nutr (2012) 0.85
Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence? Metab Brain Dis (2012) 0.85
Branched-chain amino acid supplementation in patients with liver diseases. J Nutr (2005) 0.85
Hepatic encephalopathy and health-related quality of life. Clin Liver Dis (2012) 0.85
Underweight eating disorder without over-evaluation of shape and weight: Atypical anorexia nervosa? Int J Eat Disord (2008) 0.85
Prevalence of sexual dysfunction among postmenopausal women with and without metabolic syndrome. J Sex Med (2011) 0.85
Elevated 1-hour postload plasma glucose levels identify subjects with normal glucose tolerance but impaired β-cell function, insulin resistance, and worse cardiovascular risk profile: the GENFIEV study. J Clin Endocrinol Metab (2013) 0.85
Update on nutritional supplementation with branched-chain amino acids. Curr Opin Clin Nutr Metab Care (2005) 0.85
Vascular risk in young women with polycystic ovary and polycystic ovary syndrome. Obstet Gynecol (2008) 0.84
A positive blood alcohol concentration is the main predictor of recurrent motor vehicle crash. Ann Emerg Med (2005) 0.84
Short-term multidisciplinary non-pharmacological intervention is effective in reducing liver fat content assessed non-invasively in patients with nonalcoholic fatty liver disease (NAFLD). Clin Res Hepatol Gastroenterol (2012) 0.84
Effects of cognitive-behavioral treatment for weight loss in family members. J Am Diet Assoc (2011) 0.83
The effect of inpatient cognitive-behavioral therapy for eating disorders on temperament and character. Behav Res Ther (2006) 0.83
Metabolic syndrome: a child is not a small adult. Int J Pediatr Obes (2008) 0.83